By Maggie Fick LONDON (Reuters) -Shares in French drugmaker Sanofi fell more than 10% on Thursday, wiping nearly $13 billion ...

Sanofi stock plummeted Thursday after the company's experimental eczema drug proved meaningfully inferior to Dupixent.

Amgen (AMGN) stock in focus as the company and Kyowa Kirin (KYKOF) report Phase 3 data showing their atopic dermatitis drug, ...

Data from the late-stage trial of amlitelimab weren’t as strong as the results seen in Phase 2, adding to doubts about a drug ...

The most effective treatments for eczema accomplish three things: They calm inflammation, bring relief from itch and restore ...

Sanofi (SNY) stock drops after Phase 3 trial results for amlitelimab, its experimental therapy for eczema, disappointed ...

Amlitelimab has been billed by Sanofi as a successor to its Regeneron-partnered, $14.5 billion blockbuster Dupixent ...

Sanofi (NASDAQ:SNY) stock took a beating Thursday after its latest eczema drug trial left Wall Street unconvinced, even ...

Sanofi stated that these positive results strengthen amlitelimab's potential as a treatment for atopic dermatitis. The company is currently conducting additional late-stage trials of the drug, which ...

French drugmaker Sanofi SA (NASDAQ:SNY) stock fell sharply Thursday after late-stage trial results for amlitelimab, its ...

Doctors have shared their top tips for travelling with eczema, offering some wise words for people who find heading to ...

Enveda has closed its second $150 million financing round of the year. The series D round, which moves Enveda’s total funding ...